Eslikarbazepine - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Antiepileptic agents

Included in the formulation

Exalieff®

pills inwards

Eysay Europe Limited United Kingdom

АТХ:

N.03.A.F The carboxamide derivatives

N.03.A.F.04 Eslicarbazepine

Pharmacodynamics:

Differently and selectively blocks the potential-dependent sodium channels of neurons, preventing their activation; as a result decreases Typical for epileptogenic activity is high-frequency impulses.

Pharmacokinetics:

After ingestion, up to 90% is absorbed, absorption is not dependent on food intake. Maximum concentrationin blood plasma is achieved after 2 hours; equilibrium concentration- 4-5 days after the start of the drug. The connection with plasma proteins is 40%.

Metabolism in the liver by glucuronation. Half-lifeis 20-24 hours Elimination by the kidneys: up to 80% unchanged, about 20% in the form of glucuronides.

Indications:

Partial epileptic seizures in patients aged 18 years and older (as part of combination therapy).

ICD-10

VI.G40-G47.G40 Epilepsy

Contraindications:

Atrioventricular blockade of II-III degree. Individual intolerance.

Carefully:

Elderly age, renal and hepatic insufficiency of mild to moderate degree, hyponatremia, intracardiac conduction disturbances.

Pregnancy and lactation:In the course of animal studies, the drug showed reproductive toxicity.Patients should be warned about the increased risk of congenital malformations in the fetus and provide an opportunity for prenatal screening.

Breastfeeding should be abolished for the duration of prescribing of eslikarbazepine, since the risk to the child can not be ruled out.

Dosing and Administration:

Inside to 400 mg once a day, the dose is raised after 1-2 weeks to 800 mg per day (up to 1200 mg per day).

Side effects:

Central and peripheral nervous system: insomnia, dizziness, irritability, depression, hyperactivity, cognitive impairment, movement coordination disorders, tremor, drowsiness, cerebellar ataxia, sedative reflex, peripheral neuropathy, dysarthria, nystagmus.

Respiratory system: dysphonia, chest pain, nosebleeds.

The system of hematopoiesis: anemia, thrombocytopenia, and leukopenia.

The cardiovascular system: orthostatic hypotension, bradycardia.

Digestive system: nausea, vomiting, dyspepsia, dry mouth, toothache, bloating, gingivitis, pancreatitis, melena.

Musculoskeletal system: Myalgia, pain in the neck and back.

Dermatological reactions: alopecia, hyperhidrosis, nail and skin damage, erythema.

Sense organs: diplopia, vertigo, tinnitus.

Urinary system: nocturia.

Reproductive system: violation of the menstrual cycle.

Allergic reactions.

Overdose:

Symptoms: shaky gait, hemiparesis.

Treatment: symptomatic. Effective hemodialysis.

Interaction:

Combines with all antiepileptic drugs.

Special instructions:

When using eslikarbazepine, it is recommended to refrain from driving a car and working with moving mechanisms.

During treatment and until the end of the current menstrual cycle after its completion, it is necessary to use barrier methods of contraception, since it is possible to reduce the effectiveness of hormonal contraceptives.

Instructions

Eslicarbazepine (Eslicarbazepinum)